About Us

Mission Statement

Our mission is to identify, develop, and market innovative biopharmaceuticals to fulfill unmet medical needs which alleviate human suffering caused by disease.

Accentia BioPharmaceuticals is a vertically-integrated biopharmaceuticals company focused on the acquisition, development and commercialization of late stage specialty pharmaceuticals and biologics for targeted therapeutics.

Corporate Background

Accentia BioPharmaceuticals, Inc (Nasdaq:ABPI) is a vertically-integrated specialty biopharmaceutical company, formed by the Hopkins Capital Group, LLC and affiliates to acquire late-stage targeted therapeutics and to use patented delivery technologies to enhance the performance of these therapeutics. The Company consists of two wholly-owned subsidiaries, and a majority, controlling interest in a third company. Together, these assets provide for a comprehensive ability to commercialize biopharmaceuticals.

Accentia partners with physicians, insurers, and pharmaceutical manufacturers to guide optimal drug development and patient care, both in the United States and in Europe.

Accentia BioPharmaceuticals is focused on the commercialization of "targeted" therapeutics in patent-protected drug delivery technologies related to respiratory, oncology and critical care. Targeted therapeutics represent a rapidly growing market in pharmaceuticals, as well as in private equity spending with nearly $700 million already invested to date in 2003. Indeed the genomic revolution now offers the key means to identify targeted therapeutics. Targeted therapeutics may be synthetic chemicals or naturally occurring products called biologics, such as nucleotides, peptides, cytokines, monoclonal antibodies, or cells which restrict their action to specific cellular targets, thereby reducing undesirable collateral damage (i.e. toxicity), while boosting efficacy. As such, their extraordinary safety profiles enhance the likelihood of accelerated access to the market and their performance profiles encourage enthusiastic adoption by specialists dealing with difficult disease states.

Accentia BioPharmaceuticals has chosen to accelerate its organic growth through a combination of mergers and acquisitions of companies, product acquisitions, and in-licensing of late-stage development products. Accentia, as a later-stage company with full capabilities from development to specialized distribution and a rich pipeline of products, is well-positioned to become a market leader in the Biopharmaceutical industry.